Story perspectives

Experts Advocate for Biosimilars: Interchangeability and Affordability Key

9/17/2025

31 4

Summary

Story summary

Leah Christl from Amgen supports keeping the interchangeability designation for biosimilars.
Sarfaraz K. Niazi urges the removal of barriers to biosimilar adoption and advocates against animal testing for their approval.
He achieved FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars.
A global view emphasizes the affordability of biotherapeutic drugs and the role of biosimilars.
McKinsey & Company identifies three key imperatives for biosimilar research and development.

1 of 1

Story summary

Leah Christl from Amgen supports keeping the interchangeability designation for biosimilars.
Sarfaraz K. Niazi urges the removal of barriers to biosimilar adoption and advocates against animal testing for their approval.
He achieved FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars.
A global view emphasizes the affordability of biotherapeutic drugs and the role of biosimilars.
McKinsey & Company identifies three key imperatives for biosimilar research and development.